• +41 91 682 20 40
  • info@elixi-int.com
  • Reserved Area
    • Login
    • Register
    • Request Document
    • Send Document
logo
  • Home
  • About Us
  • Services
  • Quality
  • News
  • Case Studies
  • Contact

Let's talk

info@yourwebsite.com
+1 (555) 123-4567

  • Search

Elixi

26 November 2020

European Commission Approves Janssen’s TREMFYA (guselkumab), a First-in-Class Treatment for Active Psoriatic Arthritis (PsA)


0 Comments2 Minutes

24 November 2020

Zokinvy (lonafarnib) is the first approved Treatment for Hutchinson-Gilford Progeria Syndrome and Some Progeroid Laminopathies


0 Comments3 Minutes

9 November 2020

New indication expands use of Brilinta (ticagrelor) beyond cardiovascular disease to patients with mild-to-moderate stroke


0 Comments4 Minutes

21 October 2020

Rekambys (rilpivirine) and Vocabria injection (cabotegravir) First long-acting injectable antiretroviral therapy for HIV


0 Comments3 Minutes

15 October 2020

Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn) first FDA approved treatment for Ebola virus


0 Comments3 Minutes

5 October 2020

Opdivo (nivolumab) in combination with Yervoy (ipilimumab) newly approved first-line treatment of adults with malignant pleural mesothelioma.


0 Comments3 Minutes

2 October 2020

Jyseleca (filgotinib), approved in the EU for the treatment of adults with moderate to severe rheumatoid arthritis


0 Comments2 Minutes

27 September 2020

Nucala (mepolizumab), First Drug to Treat Group of Rare Blood Disorders in Nearly 14 Years


0 Comments3 Minutes

21 September 2020

Velphoro (sucroferric oxyhydroxide) has been approved for the treatment of children with chronic kidney disease


0 Comments2 Minutes

18 September 2020

New indication for Olumiant (baricitinib) as oral treatment for moderate to severe atopic dermatitis


0 Comments3 Minutes

  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 13

Warning:

A cybersecurity incident is under investigation. Please be carefull with emails or phone calls that correctly mention your name, role, or current transactions. Elixi’s crisis team is working to limit any harmful impact, as the security of our clients’ and suppliers’ data is Elixi’s top priority. For any clarification, you can contact: DPO@elixi-int.com

Si è verificato un evento di sicurezza informatica in corso di analisi. Vi invitiamo a prestare massima attenzione messaggi di posta elettronica o telefonate che citano correttamente il vostro nome, la funzione o operazioni realmente avvenute. Il crisis team di Elixi sta lavorando per limitare ogni conseguenza dannosa, perchè la sicurezza dei dati dei nostri clienti e dei fornitori è la nostra priorità di Elixi. Per ogni chiarimento potete contattare: DPO@elixi-int.com